SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-487111"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-487111" > Preclinical InVivo ...

Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1

Sánchez, Javier (författare)
Uppsala universitet,Institutionen för farmaci,F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland.
Nicolini, Valeria (författare)
Roche Innovat Ctr Zurich, Roche Pharma Res & Early Dev, Schlieren, Switzerland.
Fahrni, Linda (författare)
Roche Innovat Ctr Zurich, Roche Pharma Res & Early Dev, Schlieren, Switzerland.
visa fler...
Waldhauer, Inja (författare)
Roche Innovat Ctr Zurich, Roche Pharma Res & Early Dev, Schlieren, Switzerland.
Walz, Antje-Christine (författare)
F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland.
Jamois, Candice (författare)
F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland.
Fowler, Stephen (författare)
F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland.
Simon, Silke (författare)
F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland.
Klein, Christian (författare)
Roche Innovat Ctr Zurich, Roche Pharma Res & Early Dev, Schlieren, Switzerland.
Umana, Pablo (författare)
Roche Innovat Ctr Zurich, Roche Pharma Res & Early Dev, Schlieren, Switzerland.
Friberg, Lena (författare)
Uppsala universitet,Institutionen för farmaci
Frances, Nicolas (författare)
F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Grenzacherstr 124, CH-4070 Basel, Switzerland.
visa färre...
 (creator_code:org_t)
2022-10-07
2022
Engelska.
Ingår i: AAPS Journal. - : Springer Nature. - 1550-7416. ; 24
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • TYRP1-TCB is a CD3 T-cell bispecific (CD3-TCB) antibody for the treatment of advanced melanoma. A tumor growth inhibition (TGI) model was developed using mouse xenograft data with TYRP1-TCB monotherapy or TYRP1-TCB plus anti-PD-Ll combination. The model was translated to humans to inform a refined clinical strategy. From xenograft mouse data, we estimated an EC50 of 0.345 mg/L for TYRP1-TCB, close to what was observed in vitro using the same tumor cell line. The model showed that, though increasing the dose of TYRP1-TCB in monotherapy delays the time to tumor regrowth and promotes higher tumor cell killing, it also induces a faster rate of tumor regrowth. Combination with anti-PD-L1 extended the time to tumor regrowth by 25% while also decreasing the tumor regrowth rate by 69% compared to the same dose of TYRP1-TCB alone. The model translation to humans predicts that if patients' tumors were scanned every 6 weeks, only 46% of the monotherapy responders would be detected even at a TYRP1-TCB dose resulting in exposures above the EC90. However, combination of TYRP1-TCB and anti-PD-L1 in the clinic is predicted to more than double the overall response rate (ORR), duration of response (DoR) and progression-free survival (PFS) compared to TYRP1-TCB monotherapy. As a result, it is highly recommended to consider development of CD3-TCBs as part of a combination therapy from the outset, without the need to escalate the CD3-TCB up to the Maximum Tolerated Dose (MTD) in monotherapy and without gating the combination only on RECIST-derived efficacy metrics.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

CD3-bispecifics
Checkpoint inhibitors
Combination
PKPD modeling

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy